RecruitingNCT05885698

MYLUNG Consortium Part 3: Observational Study

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)

Sponsor

US Oncology Research

Enrollment

7,500 participants

Start Date

Jan 30, 2023

Study Type

OBSERVATIONAL

Conditions

Carcinoma, Non-Small Cell Lung

Summary

This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is building a research database tracking real-world treatment outcomes for adults with non-small cell lung cancer (NSCLC), from early stage to metastatic disease, to better understand how people respond to systemic (whole-body) treatments. **You may be eligible if...** - You are 18 years old or older - You have been newly diagnosed with non-small cell lung cancer at any stage (early, locally advanced, or metastatic) - Your doctor has recommended systemic treatment (like chemotherapy, immunotherapy, or targeted therapy) - You are enrolled within 30 days of starting systemic therapy **You may NOT be eligible if...** - You have been on systemic therapy for more than 30 days before enrolling - You have developed metastatic disease within 12 months of completing prior adjuvant or neoadjuvant therapy - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(17)

Southern Cancer Center, PC

Daphne, Alabama, United States

Arizona Oncology Associates, PC - NAHOA

Prescott Valley, Arizona, United States

Rocky Mountain Cancer Center

Denver, Colorado, United States

Cancer Care Centers of Brevard, Inc.

Palm Bay, Florida, United States

Woodlands Medical Specialists, PA

Pensacola, Florida, United States

Affiliated Oncologists, LLC

Chicago Ridge, Illinois, United States

Illinois Cancer Specialists

Niles, Illinois, United States

Maryland Oncology Hematology, P.A.

Silver Spring, Maryland, United States

Minnesota Oncology Hematology, P.A.

Minneapolis, Minnesota, United States

New York Oncology Hematology, P.C.

Albany, New York, United States

Oncology Hematology Care Clinical Trials, LLC

Cincinnati, Ohio, United States

Willamette Valley Cancer Institute and Research Center

Eugene, Oregon, United States

Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Blacksburg, Virginia, United States

Virginia Cancer Specialists, PC

Fairfax, Virginia, United States

Virginia Oncology Associates

Newport News, Virginia, United States

Shenandoah Oncology, P.C.

Winchester, Virginia, United States

Northwest Cancer Specialists, P.C.

Vancouver, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05885698

Related Trials

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT0723069160 locations

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

NCT0722702515 locations

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428110 locations

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

NCT0611678615 locations

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076200 locations